Literature DB >> 25617172

Parathyroid hormone therapy for hypoparathyroidism.

Natalie E Cusano1, Mishaela R Rubin2, John P Bilezikian3.   

Abstract

Hypoparathyroidism is a disease characterized by hypocalcemia and insufficient parathyroid hormone (PTH). It is a rare disorder that has been given an orphan disease designation in the United States and European Union. Hypoparathyroidism is the only endocrine deficiency disease for which the missing hormone, PTH, is not yet an approved therapy. Conventional therapy includes calcium and active vitamin D supplementation, often in large doses. Although serum calcium can be controlled with conventional therapy, it can be a challenge and, moreover, does not address other aspects of the disease, such as abnormal skeletal features and reduced quality of life. This review focuses on PTH replacement therapy in hypoparathyroidism, utilizing the full-length molecule PTH(1-84) as well as the fully active but truncated form PTH(1-34). PTH therapy addresses some aspects of the disease not ameliorated with conventional therapy.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  PTH(1-34); PTH(1-84); hypoparathyroidism; parathyroid hormone; teriparatide

Mesh:

Substances:

Year:  2014        PMID: 25617172      PMCID: PMC4306807          DOI: 10.1016/j.beem.2014.09.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  35 in total

Review 1.  Mini-review: new therapeutic options in hypoparathyroidism.

Authors:  Natalie E Cusano; Mishaela R Rubin; James Sliney; John P Bilezikian
Journal:  Endocrine       Date:  2012-02-07       Impact factor: 3.633

2.  Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial.

Authors:  T Sikjaer; L Rolighed; A Hess; A Fuglsang-Frederiksen; L Mosekilde; L Rejnmark
Journal:  Osteoporos Int       Date:  2014-04-01       Impact factor: 4.507

3.  Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.

Authors:  John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

4.  Safety of osteoanabolic therapy: a decade of experience.

Authors:  Cristiana Cipriani; Cristiana Capriani; Dinaz Irani; John P Bilezikian
Journal:  J Bone Miner Res       Date:  2012-12       Impact factor: 6.741

5.  Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.

Authors:  Rachel I Gafni; Jaime S Brahim; Panagiota Andreopoulou; Nisan Bhattacharyya; Marilyn H Kelly; Beth A Brillante; James C Reynolds; Hua Zhou; David W Dempster; Michael T Collins
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

6.  Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism.

Authors:  Karen K Winer; Bo Zhang; Joseph A Shrader; Donna Peterson; Michaele Smith; Paul S Albert; Gordon B Cutler
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

7.  Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D.

Authors:  Wiebke Arlt; Christian Fremerey; Frank Callies; Martin Reincke; Peter Schneider; Wolfgang Timmermann; Bruno Allolio
Journal:  Eur J Endocrinol       Date:  2002-02       Impact factor: 6.664

8.  Therapy of hypoparathyroidism with intact parathyroid hormone.

Authors:  M R Rubin; J Sliney; D J McMahon; S J Silverberg; J P Bilezikian
Journal:  Osteoporos Int       Date:  2010-01-22       Impact factor: 4.507

9.  Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.

Authors:  John L Vahle; Masahiko Sato; Gerald G Long; Jamie K Young; Paul C Francis; Jeffery A Engelhardt; Michael S Westmore; Yanfei Linda; James B Nold
Journal:  Toxicol Pathol       Date:  2002 May-Jun       Impact factor: 1.902

10.  Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density.

Authors:  Maira L Mendonça; Francisco A Pereira; Marcello H Nogueira-Barbosa; Lucas M Monsignore; Sara R Teixeira; Plauto Ca Watanabe; Lea Mz Maciel; Francisco Ja de Paula
Journal:  BMC Endocr Disord       Date:  2013-01-03       Impact factor: 2.763

View more
  10 in total

1.  Hypoparathyroidism: Less Severe Hypocalcemia With Treatment With Vitamin D2 Compared With Calcitriol.

Authors:  Elizabeth A Streeten; Yasaman Mohtasebi; Manige Konig; Lisa Davidoff; Kathleen Ryan
Journal:  J Clin Endocrinol Metab       Date:  2017-05-01       Impact factor: 5.958

Review 2.  Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Rev Endocr Metab Disord       Date:  2020-11-16       Impact factor: 6.514

Review 3.  Bone imaging in hypoparathyroidism.

Authors:  B C Silva; M R Rubin; N E Cusano; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-08-30       Impact factor: 4.507

4.  Prolonged Pharmacokinetic and Pharmacodynamic Actions of a Pegylated Parathyroid Hormone (1-34) Peptide Fragment.

Authors:  Jun Guo; Ashok Khatri; Akira Maeda; John T Potts; Harald Jüppner; Thomas J Gardella
Journal:  J Bone Miner Res       Date:  2016-09-09       Impact factor: 6.741

5.  Afebrile Seizures as Initial Symptom of Hypocalcemia Secondary to Hypoparathyroidism.

Authors:  Anastasia Gkampeta; Eftyxia Kouma; Anastasia Touliopoulou; Efstathios Aggelopoulos; Eleni Vourti
Journal:  J Neurosci Rural Pract       Date:  2016-12

6.  Site-Specific Difference of Bone Geometry Indices in Hypoparathyroid Patients.

Authors:  Hye Sun Park; Da Hea Seo; Yumie Rhee; Sung Kil Lim
Journal:  Endocrinol Metab (Seoul)       Date:  2017-02-06

7.  Postoperative Chronic Hypoparathyroidism and Quality of Life After Total Thyroidectomy.

Authors:  Camilla Uhre Jørgensen; Preben Homøe; Morten Dahl; Mette Friberg Hitz
Journal:  JBMR Plus       Date:  2021-03-16

8.  Teriparatide Replacement Therapy for Hypoparathyroidism During Treatment With Lenvatinib for Advanced Thyroid Cancer: A Case Report.

Authors:  Tommaso Porcelli; Francesca Sessa; Angela Caputo; Christian Catalini; Domenico Salvatore
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-17       Impact factor: 5.555

Review 9.  Current treatment of hypoparathyroidism: Theory versus reality waiting guidelines for children and adolescents.

Authors:  Salvatore Di Maio; Ashraf T Soliman; Vincenzo De Sanctis; Christos C Kattamis
Journal:  Acta Biomed       Date:  2018-03-27

Review 10.  Hypoparathyroidism in Pregnancy and Lactation: Current Approach to Diagnosis and Management.

Authors:  Dalal S Ali; Karel Dandurand; Aliya A Khan
Journal:  J Clin Med       Date:  2021-03-29       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.